Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Baxter
Boehringer Ingelheim
Moodys
McKesson
Merck
Express Scripts

Last Updated: September 25, 2022

NIASPAN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Niaspan, and when can generic versions of Niaspan launch?

Niaspan is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in NIASPAN is niacin. There are fourteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the niacin profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Niaspan

A generic version of NIASPAN was approved as niacin by BARR on April 14th, 2005.

  Try it Free

Drug patent expirations by year for NIASPAN
Drug Prices for NIASPAN

See drug prices for NIASPAN

Drug Sales Revenue Trends for NIASPAN

See drug sales revenues for NIASPAN

Recent Clinical Trials for NIASPAN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cortria CorporationPhase 1
PPDPhase 1
Pharmena North AmericaPhase 1

See all NIASPAN clinical trials

Pharmacology for NIASPAN
Drug ClassNicotinic Acid

US Patents and Regulatory Information for NIASPAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-004 Jul 28, 1997 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-002 Jul 28, 1997 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN TITRATION STARTER PACK niacin TABLET, EXTENDED RELEASE;ORAL 020381-005 Jul 28, 1997 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for NIASPAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-002 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-001 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-002 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
Abbvie NIASPAN niacin TABLET, EXTENDED RELEASE;ORAL 020381-003 Jul 28, 1997 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for NIASPAN

See the table below for patents covering NIASPAN around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 0999844 See Plans and Pricing
Finland 991895 See Plans and Pricing
Australia 8605298 See Plans and Pricing
Finland 991896 See Plans and Pricing
Finland 19991895 See Plans and Pricing
Canada 2283159 COMPOSITIONS D'ACIDE NICOTINIQUE PERMETTANT DE TRAITER L'HYPERLIPIDEMIE ET PROCEDES CONNEXES (NICOTINIC ACID COMPOSITIONS FOR TREATING HYPERLIPIDEMIA AND RELATED METHODS THEREFOR) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Baxter
Johnson and Johnson
Boehringer Ingelheim
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.